Corbus Pharmaceuticals (CRBP) News Today → America could fall from this event (From Porter & Company) (Ad) Free CRBP Stock Alerts $42.99 +0.12 (+0.28%) (As of 05/14/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 13 at 8:41 PM | msn.comRBC Capital Initiates Coverage of Corbus Pharmaceuticals Holdings (CRBP) with Outperform RecommendationMay 13 at 7:34 AM | marketbeat.comCorbus Pharmaceuticals (NASDAQ:CRBP) Receives New Coverage from Analysts at Royal Bank of CanadaRoyal Bank of Canada initiated coverage on Corbus Pharmaceuticals in a report on Monday. They set an "outperform" rating and a $77.00 price target for the company.May 13 at 7:00 AM | americanbankingnews.comStockNews.com Downgrades Corbus Pharmaceuticals (NASDAQ:CRBP) to SellMay 11 at 6:15 AM | americanbankingnews.comCorbus Pharmaceuticals (NASDAQ:CRBP) Price Target Raised to $60.00May 9, 2024 | globenewswire.comCorbus Pharmaceuticals to Participate in the 2024 RBC Capital Markets Global Healthcare ConferenceMay 9, 2024 | seekingalpha.comCRBP Corbus Pharmaceuticals Holdings, Inc.May 8, 2024 | marketbeat.comCorbus Pharmaceuticals (NASDAQ:CRBP) Price Target Raised to $60.00 at OppenheimerOppenheimer lifted their price objective on shares of Corbus Pharmaceuticals from $58.00 to $60.00 and gave the company an "outperform" rating in a research note on Wednesday.May 7, 2024 | investorplace.comCRBP Stock Earnings: Corbus Pharmaceuticals Beats EPS for Q1 2024May 1, 2024 | globenewswire.comCorbus Pharmaceuticals to Participate in the BTIG Obesity Health ForumApril 24, 2024 | globenewswire.comCorbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual MeetingApril 21, 2024 | seekingalpha.comNeutral On Corbus Pharmaceuticals' Financials And Clinical Progress In OncologyApril 20, 2024 | finance.yahoo.com7 A-Rated Aggressive Biotech Stocks to Bet On in 2024April 19, 2024 | investorplace.comThese 3 Small-Cap Stocks Are Up 304% in 2024. Can They Run Higher?April 16, 2024 | msn.comHere's What Could Help Corbus Pharmaceuticals (CRBP) Maintain Its Recent Price StrengthApril 14, 2024 | marketbeat.comCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Short Interest UpdateCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) was the target of a large increase in short interest in the month of March. As of March 31st, there was short interest totalling 475,600 shares, an increase of 17.8% from the March 15th total of 403,800 shares. Based on an average daily volume of 912,800 shares, the days-to-cover ratio is presently 0.5 days. Currently, 4.6% of the company's stock are short sold.April 2, 2024 | globenewswire.comCorbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADCMarch 27, 2024 | marketbeat.comShort Interest in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Expands By 560.9%Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) was the target of a significant increase in short interest in March. As of March 15th, there was short interest totalling 403,800 shares, an increase of 560.9% from the February 29th total of 61,100 shares. Approximately 3.9% of the shares of the company are short sold. Based on an average daily volume of 886,400 shares, the days-to-cover ratio is currently 0.5 days.March 22, 2024 | nasdaq.comCRBP Factor-Based Stock AnalysisMarch 17, 2024 | 247wallst.comBuffett Can't Get Enough of This Stock, Plus Other Insider BuyingMarch 14, 2024 | marketbeat.comShort Interest in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Decreases By 34.2%Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) saw a significant decrease in short interest in February. As of February 29th, there was short interest totalling 61,100 shares, a decrease of 34.2% from the February 14th total of 92,900 shares. Based on an average daily trading volume, of 831,100 shares, the short-interest ratio is currently 0.1 days. Approximately 0.6% of the company's shares are sold short.March 13, 2024 | msn.comCorbus Pharmaceuticals files for $300M mixed shelf offeringMarch 12, 2024 | finanznachrichten.deCorbus Pharmaceuticals Holdings, Inc.: Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate UpdateMarch 12, 2024 | globenewswire.comCorbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate UpdateMarch 12, 2024 | insidertrades.comInsider Buying: Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Major Shareholder Buys 250,000 Shares of StockMarch 11, 2024 | marketbeat.comCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Major Shareholder Cormorant Asset Management, Lp Buys 250,000 SharesCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) major shareholder Cormorant Asset Management, Lp purchased 250,000 shares of the firm's stock in a transaction on Thursday, March 7th. The stock was acquired at an average cost of $40.05 per share, for a total transaction of $10,012,500.00. Following the completion of the purchase, the insider now owns 1,725,000 shares in the company, valued at approximately $69,086,250. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Large shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.March 11, 2024 | finance.yahoo.comCRBP Apr 2024 25.000 putMarch 11, 2024 | finance.yahoo.comCRBP Mar 2024 45.000 putMarch 10, 2024 | finance.yahoo.comCRBP Jun 2024 50.000 putMarch 10, 2024 | finance.yahoo.comCRBP Jun 2024 50.000 callMarch 8, 2024 | investorplace.comAll Three of Our Analysts AgreeMarch 7, 2024 | finance.yahoo.comCRBP Mar 2024 40.000 callMarch 6, 2024 | realmoney.thestreet.comCorbus Pharmaceuticals just upgraded at Jefferies, here's whyMarch 6, 2024 | marketbeat.comCorbus Pharmaceuticals (NASDAQ:CRBP) Stock Rating Upgraded by Jefferies Financial GroupJefferies Financial Group upgraded Corbus Pharmaceuticals from a "hold" rating to a "buy" rating and increased their target price for the stock from $4.00 to $46.00 in a report on Wednesday.March 6, 2024 | globenewswire.comCorbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity SummitMarch 4, 2024 | marketbeat.comCorbus Pharmaceuticals (CRBP) Scheduled to Post Quarterly Earnings on TuesdayCorbus Pharmaceuticals (NASDAQ:CRBP) will be releasing earnings on Tuesday, March 5, Yahoo Finance reports.February 28, 2024 | markets.businessinsider.comCorbus Pharmaceuticals Names Dominic Smethurst CMOFebruary 28, 2024 | globenewswire.comCorbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical OfficerFebruary 28, 2024 | marketbeat.comCorbus Pharmaceuticals (NASDAQ:CRBP) Stock Price Passes Above 50 Day Moving Average of $14.77Corbus Pharmaceuticals (NASDAQ:CRBP) Share Price Passes Above 50-Day Moving Average of $14.77February 25, 2024 | finance.yahoo.comCorbus Pharmaceuticals Holdings Inc (3371.MU)February 18, 2024 | finance.yahoo.comACAD Mar 2024 35.000 putFebruary 17, 2024 | finance.yahoo.comACAD Mar 2024 36.000 callFebruary 12, 2024 | marketbeat.comShort Interest in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Rises By 1,553.7%Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) was the target of a large growth in short interest during the month of January. As of January 31st, there was short interest totalling 464,700 shares, a growth of 1,553.7% from the January 15th total of 28,100 shares. Approximately 4.5% of the shares of the company are sold short. Based on an average daily volume of 734,800 shares, the days-to-cover ratio is currently 0.6 days.February 7, 2024 | msn.comCorbus Pharmaceuticals Announces Chief Scientific Officer ResignationFebruary 6, 2024 | finance.yahoo.comCorbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceFebruary 6, 2024 | msn.comCorbus Pharmaceuticals Shares Updated Corporate InsightsFebruary 5, 2024 | marketbeat.comCorbus Pharmaceuticals stock: An explosive 342% YTD surgeShares of CRBP have already experienced a meteoric rise of over 300% year-to-date, thanks to early but promising data from its Phase 1 trial.February 3, 2024 | morningstar.comCorbus Pharmaceuticals Holdings IncFebruary 2, 2024 | finance.yahoo.comCorbus Pharmaceuticals Announces Closing of $94.5 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional SharesFebruary 2, 2024 | msn.comCorbus Pharmaceuticals Strikes Deal for Public Stock OfferingFebruary 1, 2024 | benzinga.comCorbus Pharmaceuticals Stock (NASDAQ:CRBP), Analyst Ratings, Price Targets, Predictions Get Corbus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRBP and its competitors with MarketBeat's FREE daily newsletter. Email Address America could fall from this event (Ad)America’s “Internal Enemies” Exposed New documentary exposes a hidden election plan in Washington D.C. that, if successful, could be more financially and culturally devastating than the dot-com blowup of 2000, the 2008 financial crisis, or the COVID crash. Click here to see how you can protect yourself today. CRBP Media Mentions By Week CRBP Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CRBP News Sentiment▼0.550.57▲Average Medical News Sentiment CRBP News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CRBP Articles This Week▼132▲CRBP Articles Average Week Get Corbus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRBP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: MRSN News ANNX News BMEA News HRTX News ANRO News KRRO News AMRN News LXRX News ADCT News NGNE News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CRBP) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersDid Intel Just Dethrone Nvidia?Chaikin AnalyticsClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsCharles Payne Demystifies OptionsUnstoppable ProsperityThe only AI company you should be looking atBehind the MarketsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperElon to Transform U.S. Economy? Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corbus Pharmaceuticals Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
